{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:33:56Z","timestamp":1790044436370,"version":"4.0.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/yco.0b013e328351a3e0","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T07:27:20Z","timestamp":1332574040000},"page":"194-200","source":"Crossref","is-referenced-by-count":100,"title":["Treatment of dual diagnosis disorders"],"prefix":"10.1097","volume":"25","author":[{"given":"Pratima","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.addbeh.2011.09.010","article-title":"Treatment of substance abusing patients with comorbid psychiatric disorders.","volume":"37","author":"Kelly","year":"2012","journal-title":"Addict Behav"},{"key":"R2-6-20210206","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1530-0277.2007.00336.x","article-title":"Treatments for patients with dual diagnosis: a review.","volume":"31","author":"Tiet","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"R3-6-20210206","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cpr.2010.11.004","article-title":"New clinical strategies of assessment of comorbidity associated with substance use disorders.","volume":"31","author":"Cosci","year":"2011","journal-title":"Clin Psychol Rev"},{"issue":"Suppl 1","key":"R5-6-20210206","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.4103\/0019-5545.69232","article-title":"Substance use and addiction research in India.","volume":"52","author":"Murthy","year":"2010","journal-title":"Indian J Psychiatry"},{"key":"R7-6-20210206","doi-asserted-by":"crossref","first-page":"s71","DOI":"10.1192\/bjp.191.50.s71","article-title":"Schizophrenia outcome measures in the wider international community.","volume":"50","author":"Isaac","year":"2007","journal-title":"Br J Psychiatry Suppl"},{"key":"R8-6-20210206","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a033429","article-title":"Psychosocial approaches to dual diagnosis.","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophr Bull"},{"key":"R9-6-20210206","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1176\/appi.ps.51.9.1126","article-title":"Dual diagnosis: 15 years of progress.","volume":"51","author":"Drake","year":"2000","journal-title":"Psychiatr Serv"},{"key":"R10-6-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.09r05119gry","article-title":"Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review.","volume":"71","author":"Baker","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R11-6-20210206","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"R12-6-20210206","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000104886","article-title":"Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders.","volume":"13","author":"San","year":"2007","journal-title":"Eur Addict Res"},{"key":"R13-6-20210206","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/mds.23227","article-title":"Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.","volume":"25","author":"Zhornitsky","year":"2010","journal-title":"Mov Disord"},{"key":"R14-6-20210206","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","article-title":"The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophr Bull"},{"key":"R15-6-20210206","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psychres.2011.05.001","article-title":"Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.","volume":"188","author":"Sevy","year":"2011","journal-title":"Psychiatry Res"},{"key":"R16-6-20210206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881111408957","article-title":"Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.","volume":"26","author":"Machielsen","year":"2012","journal-title":"J Psychopharmacol"},{"key":"R17-6-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hup.1089","article-title":"The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia.","volume":"25","author":"Kim","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"R18-6-20210206","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biopsych.2006.03.074","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid posttraumatic stress disorder.","volume":"60","author":"Petrakis","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R19-6-20210206","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/NMD.0b013e3182214297","article-title":"Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence.","volume":"199","author":"Ralevski","year":"2011","journal-title":"J Nerv Ment Dis"},{"key":"R20-6-20210206","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","article-title":"Substance abuse and schizophrenia: pharmacotherapeutic intervention.","volume":"34","author":"Green","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"R21-6-20210206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000324480","article-title":"Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder.","volume":"17","author":"Morrens","year":"2011","journal-title":"Eur Addict Res"},{"key":"R22-6-20210206","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archpsyc.63.4.426","article-title":"A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.","volume":"63","author":"Bellack","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R23-6-20210206","doi-asserted-by":"crossref","first-page":"c6325","DOI":"10.1136\/bmj.c6325","article-title":"Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial.","volume":"341","author":"Barrowclough","year":"2010","journal-title":"BMJ"},{"key":"R24-6-20210206","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archpsyc.64.10.1180","article-title":"The impact of comorbidity of mental and physical conditions on role disability in the US adult household population.","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R25-6-20210206","first-page":"46S","article-title":"Valproate in the treatment of bipolar disorder and comorbid substance abuse: a 24-week open label trial.","volume":"61","author":"Sattar","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R26-6-20210206","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","article-title":"Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.","volume":"62","author":"Salloum","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R27-6-20210206","first-page":"37","article-title":"Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism.","volume":"6","author":"Azorin","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R28-6-20210206","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/JCP.0b013e318166f50d","article-title":"Quetiapine for the treatment of cocaine dependence: an open-label trial.","volume":"28","author":"Kennedy","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R29-6-20210206","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4088\/JCP.v66n1011","article-title":"Reduction of opioid-withdrawal symptoms with quetiapine.","volume":"66","author":"Pinkofsky","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R30-6-20210206","first-page":"167","article-title":"Quetiapine in substance use disorders, abuse and dependence possibility: a review in Turkish.","volume":"21","author":"Erdogan","year":"2010","journal-title":"Turk Psikiyatri Derg"},{"key":"R31-6-20210206","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1176\/appi.ajp.162.9.1755-a","article-title":"Intravenous quetiapine abuse.","volume":"162","author":"Hussain","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R32-6-20210206","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.2007.164.1.173a","article-title":"Intravenous quetiapine-cocaine use (Q-ball).","volume":"164","author":"Waters","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R33-6-20210206","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hup.944","article-title":"Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.","volume":"23","author":"Martinotti","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R34-6-20210206","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1530-0277.2010.01270.x","article-title":"A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence.","volume":"34","author":"Stedman","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"R35-6-20210206","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4088\/JCP.v69n0502","article-title":"A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders.","volume":"69","author":"Brown","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R36-6-20210206","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","article-title":"A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.","volume":"33","author":"Brown","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"R37-6-20210206","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2004.07.016","article-title":"Antidepressant treatment of co-occurring depression and alcohol dependence.","volume":"56","author":"Pettinati","year":"2004","journal-title":"Biol Psychiatry"},{"key":"R38-6-20210206","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am J Psychiatry"},{"key":"R39-6-20210206","first-page":"S31","article-title":"Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse Med J","volume":"195","author":"Hides","year":"2011","journal-title":"Aust"},{"key":"R40-6-20210206","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"61","author":"Grant","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R41-6-20210206","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jsat.2009.12.003","article-title":"Relationship between anxiety disorders and opiate dependence--a systematic review of the literature: implications for diagnosis and treatment.","volume":"38","author":"Fatseas","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"R42-6-20210206","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3928\/00485713-20081101-01","article-title":"Anxiety disorders with comorbid substance use disorders: diagnostic and treatment considerations.","volume":"38","author":"Back","year":"2008","journal-title":"Psychiatr Ann"},{"key":"R43-6-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.drugalcdep.2008.02.009","article-title":"Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.","volume":"96","author":"Wilens","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R44-6-20210206","first-page":"573","article-title":"Randomized, controlled trial of atomoxetine for attention-deficithyperactivity disorder in adolescents with substance use disorder.","volume":"49","author":"Thurstone","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R45-6-20210206","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1521-0391.2010.00076.x","article-title":"A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.","volume":"19","author":"McRae-Clark","year":"2010","journal-title":"Am J Addict"},{"key":"R46-6-20210206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00213-011-2373-6","article-title":"Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.","volume":"219","author":"Dutra","year":"2012","journal-title":"Psychopharmacol (Berl)"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/YCO.0b013e328351a3e0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:37:44Z","timestamp":1786048664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001504-201205000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e328351a3e0","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}